Trends in Combination Antipsychotic Use Among Persons With Commercial Insurance: A Data Snapshot

Innovations in Clinical Neuroscience

Robert A. Forbes¹  Zhenchao Guo¹  Leslie Citrome¹  Iftekhar Kalsekar¹  Tony Hebden¹ 

[1] Dr. Citrome is with the Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York; Drs. Kalsekar, Guo, and Hebden are with Bristol-Myers Squibb, Plainsboro, New Jersey Dr. Forbes is with Otsuka Pharmaceutical Development and Commercialization, Princeton, New Jersey.

关键词: Antipsychotic;    bipolar disorder;    combination therapy;    commercially insured;    depression;    outpatient;    schizophrenia;   

DOI  :  

学科分类：精神健康和精神病学

来源: Matrix Medical Communications, LLC

【 摘 要 】

In this data snapshot, the IMS PharMetrics Database was examined to assess the prevalence of combination antipsychotic therapy for the years 2003 through 2009 among 122,349 commercially insured adult individuals with bipolar disorder, depression, or schizophrenia. Although all three diagnostic groups were associated with varying amounts of combination antipsychotic use that included aripiprazole, olanzapine, quetiapine, risperidone and ziprasidone, persons with schizophrenia exhibited the highest rates. These findings indicate that from the perspective of “practice-based evidence,” providers see value in combination therapy.

【 授权许可】

Unknown